The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

“…Other studies from other investigators using alternate forms of mesalamine are currently underway. 19 The results from this pilot study were not meant to change current practice given the small number of patients studied. However, if we use the results from this and other maintenance trials regarding the relapse rate at 6 months, a comparative study with 2-year follow up would require 410 patients in each arm.…”

Development of Colon-targeted Microsponges for the Treatment of Inflammatory Bowel Disease

“…Microsponges are also capable of delivering pharmaceutical active ingredients efficiently at a minimal dose to targeted site, which reduces severe systemic degradation [9,10] . Mesalamine (5-aminosalicylic acid, mesalazine) is an antiinflammatory drug used to treat IBD [11] , which is readily metabolized in the intestinal mucosal wall and in the liver and this metabolism can be overcome by formulating mesalamine as colontargeted microsponges prepared using acid resistant polymers [12] .…”

Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease

“…A study designed to directly assess dose dependency of response suggested a plateau in treatment effect around 3.0 g/day 5-ASA without further benefit at higher doses [Kruis et al 2003]. The ASCEND trials were a series of dose-finding trials for 5-ASA in UC.…”